Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)
Fluticasone Propionate And Salmeterol Powder
Product Images NDC 66993-586
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 66993-586). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Prasco Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)
Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)
This appears to be a graph showing the change in forced expiratory volume (FEV) over 12 weeks for three treatments: fluticasone propionate/salmeterol 100/50mg twice daily, fluticasone propionate 100mg twice daily plus salmeterol 50mg twice daily, and placebo. The graph shows that both of the fluticasone/salmeterol treatments resulted in increased FEV over the 12 weeks, while the placebo treatment did not. The endpoint for the fluticasone propionate/salmeterol treatment was around 87, compared to around 85 for the other two treatments.*
Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)
This is a graph showing the percent change in FEV4 (Forced Expiratory Volume in 4 seconds) over time for four different treatments: Fluticasone propionate/salmeterol 100/50 µg twice daily (N = 87), Salmeterol 50 µg twice daily (N = 86), Fluticasone propionate 100 µg twice daily (N = 85), and Placebo (N=77). The x-axis represents the days of the study, and the y-axis represents the percentage change in FEV4. However, there is no information on the study's objective or duration, and no conclusions can be drawn based on this graph alone.*
Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)
This appears to be a graph showing the change in Forced Expiratory Volume (FEV) over time for different treatment groups. The treatments include Fluticasone propionate/salmeterol, Salmeterol, Fluticasone propionate, and a Placebo, with each group having a different number of participants (N). The x-axis shows the time up to 12 weeks, and the y-axis shows the percentage change in FEV relative to the Day 1 Baseline measurement. The graph seems to indicate that the group treated with Fluticasone propionate/salmeterol had the largest improvement in FEV compared to the other treatment groups.*
Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)
This text appears to be reporting results from a medical study comparing the effectiveness of three different treatments for a respiratory condition, including a combination of fluticasone propionate and salmeterol, salmeterol alone, and a placebo. The text includes graphs tracking the participants' lung function over the course of the study (measured in mL). However, the specific results are not clear without further context or interpretation.*
Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)
This text appears to be a clinical study report on the use of Fluticasone Propionate and Salmeterol inhalers for COPD patients. It details the dosages given and the results of the study as determined by baseline FEV1 measurements. The text includes a graph showing the results at various endpoints.*
Figure A (Fp Sal Spl Graphic 08)
Putiasone and Salmeterol DISKUS is an inhaler powder used for treating asthma and chronic obstructive pulmonary disease (COPD). The inhaler comes with a mouthpiece and lever. The rest of the text is not available.*
Figure B (Fp Sal Spl Graphic 09)
Figure C (Fp Sal Spl Graphic 10)
Ifu Figure D (Fp Sal Spl Graphic 11)
Figure E (Fp Sal Spl Graphic 12)
Figure F (Fp Sal Spl Graphic 13)
Ifu Figure G (Fp Sal Spl Graphic 14)
Figure H (Fp Sal Spl Graphic 15)
Fluticasone Propionate-salmeterol Diskus 100-50 Mcg Carton (Fp Sal Spl Graphic 16)
This is a product description for a prescription medication with the NDC number 66993-584-97. The medication is called Fluticasone Propionate/Salmeterol DISKUS Inhalation Powder and is only for oral inhalation. Each blister contains 100 mcg of fluticasone propionate and 72.5 mcg of salmeterol xinafoate (equivalent to 50mcg of salmeterol base) with lactose. It also includes a DISKUS Inhalation Device which contains one foil strip of 60 blisters.*
Fluticasone Propionate-salmeterol Diskus 250-50 Mcg Carton (Fp Sal Spl Graphic 17)
This is a prescription drug called "Fluticasone Propionate/Salmeterol DISKUS Inhalation Powder" by Prasco. It comes as a device that contains 60 blisters, each blister has 250 mcg of fluticasone propionate and 72.5 mcg of salmeterol xinafoate. It is meant to be taken orally by inhalation and each blister has lactose.*
Fluticasone Propionate-salmeterol Diskus 500-50 Mcg Carton (Fp Sal Spl Graphic 18)
This is a prescription drug with NDC code 66993-586-97. It is a combination of Fluticasone Propionate and Salmeterol in a Diskus inhalation powder form that contains 500 mcg/50 mcgq. It is used for oral inhalation only and each blister contains 500 mcg of fluticasone propionate and 72.5 mcg of salmeterol xinafoate, equivalent to 50 mcg of salmeterol base. The drug comes with one Diskus inhalation device containing one foil strip of 60 blisters.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
